Proton pump inhibitors are a class of novel drugs that are the most potent acid suppressors on the market today. Since omeprazole’s introduction in 1990, they have been clinically proven to be better than H2RAs. Over the past decade, their use has been scrutinized because of several harmful disease associations like C. difficile infection, Fractures, Magnesium, Dementia, and H.Pylori.
How would you handle a patient who wants to begin long-term PPI use?
What would your discussion with them entail?
In what patients or disease states would you not recommend PPI use?
What if H. Pylori is found to be present?
You may wish to read the portion of clopidogrel’s package insert [link below] regarding pharmacogenomics as well as the article found in Medscape [link below] regarding genetics in pharmacotherapy before answering the last question. Pharmacogenomics is, and will become, an increasingly more significant part of care as we move forward.
After reviewing the package insert for clopidogrel and available evidence regarding this combination, what would you recommend if a patient is taking esomeprazole and clopidogrel together?
PEER-REVIEWED SCHOLARLY WRITTEN ARTICLE 2018 and up.
MEDSCAPE IS NOT ACCEPTED
